12th International Conference of Pharmaceutical Sciences

Drug repositioning has been an important ally in the search for new antifungal drugs. Statins are drugs that act to prevent sterol synthesis in both humans and fungi and for this reason they are promising strategies to combat mycoses1,2. We evaluated the antifungal activity of atorvastatin by in vitro tests to determine the minimum inhibitory concentration3 against azole resistant Candida albicans. Moreover, the efficacy of atorvastatin-containing vaginal emulgels (0.75%, 1.5% and 3% w/w) in an in vivo experimental model of vulvovaginal candidiasis4 was evaluated. The results showed that atorvastatin MIC against C. albicans was 31.25 µg / mL. In anti-CVV activity, the group treated with vaginal emulgel containing 3.0% atorvastatin showed a 65% reduction in fungal load after 9 days of treatment. Therefore, atorvastatin may be a promising drug for the treatment of this opportunistic disease.